Literature DB >> 10782895

Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours.

C Kuhnen1, M Lehnhardt, E Tolnay, T Muehlberger, P M Vogt, K M Müller.   

Abstract

Vascular endothelial growth factor (VEGF) is an important cytokine especially in the process of tumour angiogenesis. A total of 46 soft-tissue sarcomas were analysed for the expression and possible secretion of VEGF by immunohistochemistry, in-situ hybridisation, and enzyme-linked immunosorbent assays (ELISA). VEGF was demonstrated immunohistochemically in tumour tissue in 45 of 46 cases. The detection of mRNA transcripts yielded evidence of synthesis of VEGF in these sarcomas. ELISA could be performed in 21 cases. Higher concentrations of VEGF were found in tumour-related intraoperatively sampled venous blood in 16 out of 21 patients (76%) than in systemic concentrations taken preoperatively. The results indicated the secretion of VEGF by tumour cells although these raised concentrations were not statistically significant. In 12 out of these 16 patients (75%) a concurrent moderate to strong immunoexpression of VEGF was detected. The relevance of VEGF blood concentrations as a potential "progress parameter" for the course of disease remains questionable. This is mainly due to the lack of statistical significance in the difference between systemic VEGF concentrations in patients and those of a control group. Further long-term follow-up studies are needed, which should include patients with tumour recurrences.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782895     DOI: 10.1007/s004320050036

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  10 in total

1.  Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.

Authors:  J Martín-Liberal; A López-Pousa; J Martín Broto; R Cubedo; O Gallego; E Brendel; O M Tirado; X García del Muro
Journal:  Invest New Drugs       Date:  2013-06-26       Impact factor: 3.850

2.  Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.

Authors:  Lu Xie; Jie Xu; Xin Sun; Xiaodong Tang; Taiqiang Yan; Rongli Yang; Wei Guo
Journal:  Oncologist       Date:  2018-12-17

Review 3.  The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Authors:  Sushma Vemulapalli; Alain Mita; Yesid Alvarado; Kamalesh Sankhala; Monica Mita
Journal:  Target Oncol       Date:  2011-04-28       Impact factor: 4.493

Review 4.  Epigenetic polypharmacology: A new frontier for epi-drug discovery.

Authors:  Daniela Tomaselli; Alessia Lucidi; Dante Rotili; Antonello Mai
Journal:  Med Res Rev       Date:  2019-06-20       Impact factor: 12.944

Review 5.  Management of angiosarcoma.

Authors:  G Thomas Budd
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

6.  Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma.

Authors:  Anil Potti; Apar Kishor Ganti; Ketki Tendulkar; Kaley Sholes; Sidharth Chitajallu; Michael Koch; Steven Kargas
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-05       Impact factor: 4.553

7.  Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma.

Authors:  M Kaya; T Wada; S Kawaguchi; S Nagoya; T Yamashita; Y Abe; H Hiraga; K Isu; M Shindoh; F Higashino; F Okada; M Tada; S Yamawaki; S Ishii
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

8.  Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix.

Authors:  J A Loncaster; R A Cooper; J P Logue; S E Davidson; R D Hunter; C M West
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

Review 9.  Anti-angiogenesis target therapy for advanced osteosarcoma (Review).

Authors:  Lu Xie; Tao Ji; Wei Guo
Journal:  Oncol Rep       Date:  2017-06-21       Impact factor: 3.906

10.  A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.

Authors:  Varun Monga; Umang Swami; Munir Tanas; Aaron Bossler; Sarah L Mott; Brian J Smith; Mohammed Milhem
Journal:  Cancers (Basel)       Date:  2018-02-17       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.